WILMINGTON, DE — AstraZeneca reported that its experimental drug tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease in a Phase III trial.
Results from the MIRANDA trial showed a statistically significant reduction in annualized exacerbation rates among former smokers and across the broader study population, which included both former and current smokers.
Patients in the trial received 300 mg of tozorakimab or a placebo every two weeks in addition to standard inhaled therapies…